

Global Clinical Development Pipeline

Updated: 12 May 2025

Phase 1		Phase 2		Phase 3		Accepted Submissions Major markets	
Sonrotoclast ● 101 B-cell malignancies ● 102 B-cell malignancies ● 103 AML/MDS ● 105 R/R MM t(11;14) ● 108 Dose ramp-up	BCL2i	BGB-16673 ● 101 B-cell malignancies ● 102 B-cell malignancies ● 104 B-cell malignancies	BTK CDAC	Zanubrutinib ● 215 B-cell malignancies	BTKi	Zanubrutinib ● 306 TN MCL ● 308 R/R MZL, R/R FL ● 309 pMN	BTKi
BGB-43395 ● 101/102 BC & Solid tumors	CDK4i	BGB-21447 ● 101 B-cell malignancies ● 102 Metastatic breast cancer	BCL2i 2G	BGB-16673 ● 101 R/R CLL ● 102 R/R CLL	BTK CDAC	BGB-16673 ● 302 R/R CLL	BTK CDAC
BGB-53038 ● 101 Solid tumors	PanKRASI	Xaluritamig⁴ ● 20180146 mCRPC	STEAPI x CD3 XmAb[®]	Sonrotoclast ● 203 R/R WM ● 204 TN CLL/SLL	BCL2i	Sonrotoclast ● 301 TN CLL ● 302 R/R MCL ● 303 R/R CLL/SLL**	BCL2i
BG-C9074¹ ● 101 Solid tumors	B7-H4 ADC	BGB-R046 ● 101 Solid tumors	IL-15 prodrug	Blinatumomab⁴ ● 20190359 Pediatric R/R BP-ALL	CD3 x CD19 BiTE[®]	Tislelizumab ● 310 1L UBC ● 314 R/R cHL	PD1 mAb
BG-60366 ● 101 Solid tumors	EGFR CDAC	BGB-B2033 ● 101 Solid tumors	GPC3 x 4-1BB BsAb	Tarlatamab⁴ ● 20230273 3L SCLC ● 20240092 2L+ SCLC**	DLL3 x CD3 BiTE[®]	Pamiparib ● 302 2L MTx gBRCAm PSOC	PARPi
BG-58067 ● 101 Solid tumors	MTA Coop. PRMT5i	BGB-B3227 ● 101 Solid tumors	MUC1 x CD16A BsAb	Zanidatamab⁵ ● 301 1L HER2+ GEA	HER2 BsAb	Tarlatamab⁴ ● 20210004 2L SCLC ● 20200041 1L ES-SCLC ● 20230016 LS-SCLC	DLL3 x CD3 BiTE[®]
BG-89894² ● 101 Solid tumors	MAT2Ai	BGB-26808 ● 101 Solid tumors	HPK1i				
BGB-45035 ● 101 Immunology & Inflammation	IRAK4 CDAC	BGB-30813 ● 101 Solid tumors	DGKζi				
BG-68501³ ● 101 BC & Solid tumors	CDK2i	BGB-A3055 ● 101 Solid tumors	CCR8 mAb				
BG-C354 ● 101 Solid tumors	B7-H3 ADC	Tislelizumab ● 103 SubQ formulation	PD1 mAb				
BG-C477 ● 101 Solid tumors	CEA ADC	BGB-B455 ● 101 Solid tumors	CLDN6 x CD3 BsAb				
BG-C137 ● 101 Solid tumors	FGFR2b ADC	Tarlatamab⁴ ● 20240124 2L+ SCLC** ● 20230298 2L+ SCLC**	DLL3 x CD3 BiTE[®]				
BG-T187 ● 101 Solid tumors	EGFR x MET TsAb						

● Heme	● Breast / Gyn	● Other Cancers
● Lung	● GI	● I&I

Accepted submissions shown for major markets US, CN, EU, JP
 1) DualityBio collaboration, 2) CSPC collaboration, 3) Ensem collaboration, 4) Amgen collaboration, 5) Zymeworks/Jazz collaboration.
 Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details
 ** Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

